Vadastuximab is a novel antibody-drug compound representing a crucial advancement in the treatment of acute myeloid leukemia (AML). This innovative therapy selectively targets CD33, a protein frequently https://prbookmarkingwebsites.com/story28358155/vadastuximab-a-deep-examination-into-cd33-directed-therapy